+353-1-416-8900REST OF WORLD
1-800-526-8630U.S. (TOLL FREE)

China Pharmaceutical & Biotechnology Review

  • ID: 583220
  • Newsletter
  • April 2017
  • Region: China
  • General Biologic
1 of 5
The China Pharmaceutical & Biotechnology Review is a monthly publication covering all aspects of the industry, delivered to subscribers via email as a PDF document. From reimbursement policy and industry reform to newly registered drugs and emerging local players, the CPB Review sheds an insightful light on China's complex and opaque marketplace. Each issue includes news briefs reviewing the key developments of the previous month, in-depth analytical articles, exclusive interviews with industry executives, and research highlights. Included are profiles of companies, products, and influential personalities in the industry.

The CPB Review is geared towards healthcare industry professionals interested in keeping track of events in China, but who do not have a pressing need for daily information or historical search capabilities. The CPB Review synthesizes current events and bigger picture trends, making sense of the dizzying pace of change in the Chinese healthcare marketplace.

What do I get with a subscription?

- You get a PDF file monthly newsletter with all the news from the month, lead articles, and capital markets overview
- You get access to the news briefs headlines and full articles daily as they are created on www.gbipharma.com
- You get a weekly email that includes the headlines and links to the articles
- You get access to any pod casts or interviews GB conducts

Subscription Includes:

Proprietary reports on the latest trends in China's pharma industry

Learn what leaders in China's healthcare industry are doing to stay ahead in China

Most inportant news briefs frome the month designed to be read for decision makers

Information collected from our revolutionary SOURCE information platform

Available in PDF and print format

Latest Issues

Issue 51

Lead articles:

- A New Leaf: Beijing moves Traditional Chinese Medicine to the front burner
Rough Tendering: Growing dissatisfaction with the “Anhui Model”

- Ralf Altmeyer on Accelerating Global Biotech Companies via Advance BioChina

Issue 50

Lead articles:

- Can the Dragon and the Elephant Tango?

- Antibiotic abuse in China

- Ming-Wei Wang on China's Drug Discovery and Development

Issue 49

Lead articles:

- Is China Cleaning Up Its Act? Pharma and the recent pollution scandal

- Dogged by rabies: China bites back at a growing epidemic

- Alex Fowkes on R&D Business Development in China
Note: Product cover images may vary from those shown
2 of 5


3 of 5
Key TOC of CPB monthly covers:

Leading articles on timely topics
Interviews with key industry leaders
Key facts and figures
Daily news clips covering:
- Policy and regulations
- Investment and finance
- Multinational and Chinese companies updates
- Research & Development
- IP & Legal
- Hospitals
Major Deals
Company Earnings
Profiles of academic and industry
Profiles of emerging and established
Chinese companies
Research Highlights
Equity Markets Review
Note: Product cover images may vary from those shown
4 of 5
- ACON Biotech (Hangzhou) Co. Ltd.
- DaAn Gene Co. Ltd. of Sun Yat-Sen University
- Joincare Pharmaceutical Group Industry Co. Ltd.
- Shanghai SynCores Technologies, Inc.
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown